 Metabolic-associated fatty liver disease, MAFLD, is a growing global health concern due to its high prevalence and severity. Liver fibrosis is the most important factor in determining the prognosis of MAFLD patients, making it essential to develop effective treatments. Recent studies have shown that multi-drug combination therapies can be used to reduce liver fibrosis and improve patient outcomes. This review provides an overview of the mechanisms behind MAFLD-related liver fibrosis, summarizes current treatment options, and highlights the potential of multi-drug combination therapies. This article was authored by Ching Fudong, Helin Bao, Chen Gang-Wang, and others.